Ivonescimab shows survival benefit in lung cancer study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducte
November 7, 2025 9:00 AM ESTThe First Phase III Study Testing Ivonescimab Now Represents the First Statistically Significant OS Benefit Achieved by an Ivonescimab-Containing Regimen
Ivonescimab Plus Chemotherapy Demonstrates Median OS of 16.8 Months vs. 14.1 Months, Respectively, for Patients Receiving Ivonescimab Plus Chemotherapy vs. Chemotherapy Alone; OS HR of 0.74 (p=0.019)
Favorable Risk-Benefit Profile Observed in This Phase III Study
MIAMI--(BUSINESS WIRE)-- Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) today noted that our partner, Akeso, Inc. (Akeso, HKEX Code: 9926.HK) published results from the Phase III HARMONi-A trial,... More
